ProQR Therapeutics (PRQR) Income towards Parent Company (2013 - 2025)
ProQR Therapeutics recorded quarterly Income towards Parent Company of -$9.1 million in Q4 2025, up 29.18% quarter-over-quarter from -$12.9 million in Q3 2025, and up 7.16% year-over-year from -$8.5 million in Q4 2024.
ProQR Therapeutics' Income towards Parent Company history runs 13 years deep, the most recent figure standing at -$9.1 million for Q4 2025.
- In Q4 2025, Income towards Parent Company rose 7.16% year-over-year to -$9.1 million; the TTM figure through Dec 2025 stood at -$47.6 million (down 56.64% YoY), while the FY2025 annual figure was -$49.1 million, down 65.51% from the prior year.
- Income towards Parent Company came in at -$9.1 million for Q4 2025 at ProQR Therapeutics, up from -$12.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$2.9 million in Q2 2024 to a low of -$23.5 million in Q3 2022.
- A 5-year average of -$12.4 million and a median of -$11.9 million in 2025 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 72.01% in 2023 and plunged 402.18% in 2025, its largest moves.
- ProQR Therapeutics' Income towards Parent Company stood at -$20.8 million in 2021, then jumped by 34.92% to -$13.6 million in 2022, then jumped by 60.85% to -$5.3 million in 2023, then tumbled by 85.19% to -$9.8 million in 2024, then rose by 7.16% to -$9.1 million in 2025.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$9.1 million, -$12.9 million, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9.13 Mn |
| Sep 30, 2025 | -12.89 Mn |
| Jun 30, 2025 | -14.56 Mn |
| Mar 31, 2025 | -10.99 Mn |
| Dec 31, 2024 | -9.84 Mn |
| Sep 30, 2024 | -9.32 Mn |
| Jun 30, 2024 | -2.90 Mn |
| Mar 31, 2024 | -8.32 Mn |
| Dec 31, 2023 | -5.31 Mn |
| Sep 30, 2023 | -6.58 Mn |
| Jun 30, 2023 | -8.70 Mn |
| Mar 31, 2023 | -9.82 Mn |
| Dec 31, 2022 | -13.57 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -14.62 Mn |
| Mar 31, 2022 | -15.84 Mn |
| Dec 31, 2021 | -20.84 Mn |
| Sep 30, 2021 | -17.74 Mn |
| Jun 30, 2021 | -19.13 Mn |
| Mar 31, 2021 | -15.21 Mn |
| Dec 31, 2020 | -16.00 Mn |
| Sep 30, 2020 | -15.69 Mn |
| Jun 30, 2020 | -4.68 Mn |
| Mar 31, 2020 | -17.72 Mn |
| Dec 31, 2019 | -20.52 Mn |
| Sep 30, 2019 | -13.51 Mn |
| Jun 30, 2019 | -13.09 Mn |
| Mar 31, 2019 | -16.09 Mn |
| Dec 31, 2018 | -14.77 Mn |
| Sep 30, 2018 | -6.93 Mn |
| Jun 30, 2018 | -8.76 Mn |
| Mar 31, 2018 | 13,094.93 |
| Dec 31, 2017 | 13.28 Mn |
| Sep 30, 2017 | 12,351.09 |
| Jun 30, 2017 | -12.49 Mn |
| Mar 31, 2017 | 11.17 Mn |
| Dec 31, 2016 | -9.52 Mn |
| Sep 30, 2016 | -11.30 Mn |
| Jun 30, 2016 | -11.25 Mn |
| Mar 31, 2016 | -9.72 Mn |
| Dec 31, 2015 | -6.71 Mn |
| Sep 30, 2015 | -7.03 Mn |
| Jun 30, 2015 | -9.53 Mn |
| Mar 31, 2015 | -131.83 Mn |
| Dec 31, 2014 | -2.55 Mn |
| Sep 30, 2014 | -4.48 Mn |
| Mar 31, 2014 | -2.54 Mn |
| Dec 31, 2013 | -2.22 Mn |
| Sep 30, 2013 | -1.16 Mn |